vTv Therapeutics completes enrollment in Phase 3 CATT1 cadisegliatin trial in type 1 diabetes
Bitget2026/10/05 12:11vTv Therapeutics completed enrollment in its Phase 3 CATT1 trial of cadisegliatin as an adjunct to insulin in type 1 diabetes. Topline results have not been presented yet; reporting is targeted for mid-2027. The study is designed to show whether cadisegliatin can lower clinically significant hypoglycemia while improving overall glucose control. Cadisegliatin is an oral, liver-selective glucokinase activator with FDA Breakthrough Therapy designation for adjunctive treatment in type 1 diabetes. Enrollment reached 166 randomized patients, positioning the program for a key readout that could shape the regulatory path. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839228) on October 05, 2026, and is solely responsible for the information contained therein.
- vTv Therapeutics completed enrollment in its Phase 3 CATT1 trial of cadisegliatin as an adjunct to insulin in type 1 diabetes.
- Topline results have not been presented yet; reporting is targeted for mid-2027.
- The study is designed to show whether cadisegliatin can lower clinically significant hypoglycemia while improving overall glucose control.
- Cadisegliatin is an oral, liver-selective glucokinase activator with FDA Breakthrough Therapy designation for adjunctive treatment in type 1 diabetes.
- Enrollment reached 166 randomized patients, positioning the program for a key readout that could shape the regulatory path.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
